Kangfeng Biotechnology’s Anti-Gastroesophageal Reflux System Receives Approval from the Drug Administration
December 17, 2025
Source: drugdu
33
On December 16, Kangfeng Bio-B (06922) issued an announcement stating that its anti-gastroesophageal reflux system received approval from the National Medical Products Administration on December 15, 2025.
The anti-gastroesophageal reflux system is a surgical instrument independently developed by the company. It consists of an implantable anti-gastroesophageal reflux device and an esophageal measuring tool. The working principle is to fix the device in the functional area of the lower esophageal sphincter outside the esophagus, and use the magnetic attraction generated by the magnetic beads in the device to enhance the tension of the lower esophageal sphincter, thereby restoring its anti-reflux function and treating gastroesophageal reflux disease.
https://finance.eastmoney.com/a/202512163593180489.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Subsidiary Signs Exclusive Licensing Agreement for GenSci098 Injection Project December 17, 2025
- Cell Metabolism | Efficacy of Akkermansia muciniphila Supplementation in Overweight/Obese Patients with Type 2 Diabetes December 17, 2025
- Major Breakthrough! China’s First Injectable Silk Fibroin Gel Enters Clinical Trials December 17, 2025
- Can AOC become the “next stop” for oligonucleotide therapy? December 17, 2025
- A global first! Two domestically developed innovative medical devices have been approved for market launch December 17, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
